AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25829156 — intervention group
Group type: COMPARATOR
Intervention: Neurectomy
Number of subjects: 20
Study 25022774 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based training (60-90 minutes)
Number of subjects: 30
Study 25022774 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 30
Study 25022774 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pre- to posttreatment data for all participants
Number of subjects: 30
Study 25022774 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Action Questionnaire‐II (AAQ‐II)
Number of subjects: 30
Study 22292861 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 148
Study 22292861 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 148
Study 22292861 — intervention group
Group type: COMPARATOR
Intervention: All message frames
Number of subjects: 148
Study 20119585 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine/100 microg fentanyl/epinephrine
Number of subjects: 61
Study 20119585 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine/saline/epinephrine
Number of subjects: 61
Study 17434069 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational brochure
Number of subjects: 198
Study 17434069 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational conversation with a trained mammography technologist
Number of subjects: 198
Study 17434069 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure together with the conversation with a trained technologist
Number of subjects: 198
Study 17434069 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 198
Study 15808032 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine sulphate
Number of subjects: 13
Study 15808032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11991886 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol nebulized with heliox
Number of subjects: 45
Study 11991886 — intervention group
Group type: COMPARATOR
Intervention: Albuterol nebulized with oxygen (control)
Number of subjects: 45
Study 9438623 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally preperitoneal (TPP) laparoscopic approach
Number of subjects: 100
Study 9438623 — intervention group
Group type: COMPARATOR
Intervention: Stoppa procedure (open)
Number of subjects: 100
Study 8192293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane Collaboration systematic reviews of RCTs
Number of subjects: 0
Study 2949023 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet cream (0.3% in men and 1% in women)
Number of subjects: 309
Study 2949023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 30513892 — intervention group
Group type: EXPERIMENTAL
Intervention: PED-t
Number of subjects: 164
Study 30513892 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 164
Study 26662998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopoietic stem cell therapy (600 × 10^6 bone marrow-derived and lineage-directed autologous cardiopoietic stem cells administered via a retention-enhanced intramyocardial injection catheter
Number of subjects: 240
Study 26662998 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 240
Study 26662998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopoietic stem cell therapy
Number of subjects: 240
Study 25070705 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of X-ray for remote consultation through an iPad
Number of subjects: 42
Study 25070705 — intervention group
Group type: COMPARATOR
Intervention: Standard approach (verbal information only, no X-ray provided remotely)
Number of subjects: 42
Study 22500711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanjie Zhitong plaster
Number of subjects: 0
Study 22500711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20577717 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (4, 8, and 16 mg)
Number of subjects: 8
Study 20577717 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (4/1, 8/2, and 16/4 mg)
Number of subjects: 8
Study 20577717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of buprenorphine
Number of subjects: 8
Study 20577717 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone combination (low and high doses)
Number of subjects: 8
Study 20577717 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular hydromorphone (2 and 4 mg)
Number of subjects: 8
Study 20577717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 20577717 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine with naloxone
Number of subjects: 8
Study 18607527 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective supportive intervention (NDSI)
Number of subjects: 168
Study 18607527 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive visual motor intervention (DVMI)
Number of subjects: 168
Study 18607527 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 168
Study 16491674 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of results provided for both arms in Experiment 1
Number of subjects: 64
Study 16491674 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of results provided for one arm only in Experiment 2
Number of subjects: 64
Study 16491674 — intervention group
Group type: EXPERIMENTAL
Intervention: Same distance movements with knowledge of results
Number of subjects: 64
Study 16491674 — intervention group
Group type: EXPERIMENTAL
Intervention: Different distance movements
Number of subjects: 64
Study 11798998 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 400
Study 11798998 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 400
Study 11798998 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 400
Study 10412778 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein apheresis (LDL-A)
Number of subjects: 27
Study 10412778 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 27
Study 7676822 — intervention group
Group type: EXPERIMENTAL
Intervention: Large collar prosthetic designs (Lubinus, HD2, Scanhip)
Number of subjects: 204
Study 7676822 — intervention group
Group type: COMPARATOR
Intervention: Flanged or tapered stem prosthetic designs (Charnley, Exeter)
Number of subjects: 204
Study 7676822 — intervention group
Group type: EXPERIMENTAL
Intervention: Large collar prosthetic designs
Number of subjects: 204
Study 1756688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg 12 hourly)
Number of subjects: 52
Study 1756688 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (400 mg every 6 hours)
Number of subjects: 52
Study 1756688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 52
Study 1756688 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 52
Study 7159502 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl‐estradiol/noretisterone (EE/NET) 35 micrograms/0.5 mg
Number of subjects: 11
Study 7159502 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl‐estradiol/noretisterone (EE/NET) 50 micrograms/1 mg
Number of subjects: 11
Study 7159502 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl‐estradiol/noretisterone (EE/NET) 35 micrograms/1 mg
Number of subjects: 11
Study 30412652 — intervention group
Group type: EXPERIMENTAL
Intervention: Static air support surfaces
Number of subjects: 308
Study 30412652 — intervention group
Group type: COMPARATOR
Intervention: Alternating pressure air mattresses
Number of subjects: 308
Study 29741911 — intervention group
Group type: EXPERIMENTAL
Intervention: Semitendinosus and Gracilis Tendon (STG) Autograft
Number of subjects: 64
Study 29741911 — intervention group
Group type: COMPARATOR
Intervention: Patellar Tendon (PT) Autograft
Number of subjects: 64
Study 27745818 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ambrisentan and tadalafil
Number of subjects: 605
Study 27745818 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (ambrisentan or tadalafil)
Number of subjects: 605
Study 24747412 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planning (SRP)
Number of subjects: 29
Study 24747412 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planning (FMSRP)
Number of subjects: 29
Study 22446022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab added to chemotherapy
Number of subjects: 845
Study 22446022 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 845
Study 19329115 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management after induced abortion with misoprostol (group 1)
Number of subjects: 96
Study 19329115 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management after spontaneous abortion (group 2)
Number of subjects: 96
Study 19329115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 96
Study 17504682 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid 300 mg per day for 6 months (Group I)
Number of subjects: 105
Study 17504682 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid 300 mg per day plus rifampin 600 mg per day for 3 months (Group II)
Number of subjects: 105
Study 15167956 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (>= 4 attacks/week)
Number of subjects: 12
Study 11245864 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually planned care and systematic clinical supervision (Experimental Ward)
Number of subjects: 22
Study 11245864 — intervention group
Group type: COMPARATOR
Intervention: Control Ward (no intervention)
Number of subjects: 22
Study 9688409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix 60 mg administered i.m. on cycle day 2, followed by a second dose of either 30 or 60 mg based on oestradiol suppression
Number of subjects: 20
Study 9688409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Number of subjects: 20
Study 8134987 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous flow irrigation
Number of subjects: 80
Study 8134987 — intervention group
Group type: COMPARATOR
Intervention: Intermittent flow irrigation
Number of subjects: 80
Study 2642605 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and chlorambucil
Number of subjects: 81
Study 2642605 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy alone
Number of subjects: 81
Study 870130 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose synthetic human calcitonin (CIBA 47175‐Ba)
Number of subjects: 8
Study 870130 — intervention group
Group type: COMPARATOR
Intervention: Radiographs and radioisotope bone scans
Number of subjects: 8
Study 31017382 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic administration (specifically L. reuteri DSM 17938 strain)
Number of subjects: 0
Study 31017382 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic administration during pregnancy and continued after birth
Number of subjects: 0
Study 31017382 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine administration of probiotics to all infants
Number of subjects: 0
Study 28727796 — intervention group
Group type: EXPERIMENTAL
Intervention: Health risk assessment (HRA) and monthly counselling sessions with a geriatrician over six months.
Number of subjects: 200
Study 28727796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 200
Study 28727796 — intervention group
Group type: COMPARATOR
Intervention: Comparison between intervention and control groups.
Number of subjects: 200
Study 25633634 — intervention group
Group type: EXPERIMENTAL
Intervention: Form‐Focused running using ChiRunning
Number of subjects: 17
Study 25633634 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐directed training with educational materials
Number of subjects: 17
Study 25633634 — intervention group
Group type: COMPARATOR
Intervention: Conventional running
Number of subjects: 17
Study 24246618 — intervention group
Group type: EXPERIMENTAL
Intervention: uBurn(©)
Number of subjects: 34
Study 24246618 — intervention group
Group type: EXPERIMENTAL
Intervention: MerseyBurns(©)
Number of subjects: 34
Study 24246618 — intervention group
Group type: COMPARATOR
Intervention: Calculator
Number of subjects: 34
Study 24246618 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 34
Study 20664555 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 46
Study 20664555 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 46
Study 18641106 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly for 12 months
Number of subjects: 56
Study 16202565 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 414
Study 16202565 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 414
Study 16202565 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 414
Study 12957344 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (0, 21, 35 or 42 mg/day)
Number of subjects: 1039
Study 10872897 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean red meat
Number of subjects: 145
Study 8941106 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.25 mg BID carvedilol (low‐dose group)
Number of subjects: 345
Study 8941106 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg BID carvedilol (medium‐dose group)
Number of subjects: 345
Study 8941106 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg BID carvedilol (high‐dose group)
Number of subjects: 345
Study 8941106 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined carvedilol groups
Number of subjects: 345
Study 8941106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study 1610414 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg b.i.d. for the first month, 240 mg b.i.d. for the second month)
Number of subjects: 30
Study 1610414 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg b.i.d. for the first month, 50 mg b.i.d. for the second month)
Number of subjects: 30
Study 1610414 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of verapamil (240 mg b.i.d.) and captopril (50 mg b.i.d.)
Number of subjects: 30
Study 3158903 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole suppositories (1 g, administered 8-hourly over 20 hours preceding surgery, then 12-hourly if applicable)
Number of subjects: 0
Study 3158903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole (500 mg infusion at the time of induction)
Number of subjects: 0
Study 3158903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both routes (suppositories and intravenous)
Number of subjects: 0
Study 3158903 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31738653 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (single low initiation dose)
Number of subjects: 1
Study 31738653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (8 cycles)
Number of subjects: 1
Study 31738653 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ibrutinib and venetoclax
Number of subjects: 1
Study 30466822 — intervention group
Group type: EXPERIMENTAL
Intervention: IV sodium bicarbonate
Number of subjects: 1161
Study 30466822 — intervention group
Group type: COMPARATOR
Intervention: IV sodium chloride
Number of subjects: 1161
Study 30466822 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetylcysteine
Number of subjects: 1161
Study 30466822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1161
Study 26866428 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping TNFi treatment
Number of subjects: 817
Study 26866428 — intervention group
Group type: COMPARATOR
Intervention: Continuation of TNFi treatment
Number of subjects: 817
Study 24707184 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive multifactorial intervention (PMI) using single-pill amlodipine/atorvastatin
Number of subjects: 1417
Study 24707184 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1417
Study 23461076 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 77
Study 23461076 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 77
Study 23461076 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prognosis
Number of subjects: 77
Study 23461076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function values
Number of subjects: 77
Study 23461076 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 77
Study 20012012 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerance (IGT)
Number of subjects: 602
Study 20012012 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta cell function
Number of subjects: 602
Study 18728908 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted evidence-based medicine intervention (didactic course + recurrent case-method learning sessions)
Number of subjects: 14
Study 18728908 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-group sessions
Number of subjects: 14
Study 16187865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot mood induction
Number of subjects: 0
Study 16187865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold mood induction
Number of subjects: 0
Study 16187865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad mood induction
Number of subjects: 0
Study 16187865 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry mood induction
Number of subjects: 0
Study 16187865 — intervention group
Group type: EXPERIMENTAL
Intervention: Musical mood induction (Study 2)
Number of subjects: 0
Study 16187865 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit manipulation of moods (Study 3)
Number of subjects: 0
Study 12067856 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg testosterone enanthate (TE) weekly
Number of subjects: 61
Study 12067856 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg testosterone enanthate (TE) weekly
Number of subjects: 61
Study 12067856 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg testosterone enanthate (TE) weekly
Number of subjects: 61
Study 12067856 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg testosterone enanthate (TE) weekly
Number of subjects: 61
Study 12067856 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg testosterone enanthate (TE) weekly
Number of subjects: 61
Study 10489659 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sertraline per day
Number of subjects: 28
Study 10489659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8756812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent enteral feeding (IEF) 18 h/d
Number of subjects: 60
Study 8756812 — intervention group
Group type: COMPARATOR
Intervention: Continuous enteral feeding (CEF) 24 h/d
Number of subjects: 60
Study 1764148 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital setting
Number of subjects: 114
Study 1764148 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth room setting
Number of subjects: 114
Study 6749959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 16
Study 6749959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31445363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumpkin Seed Oil (PSO) 3g/day
Number of subjects: 23
Study 31445363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 28403351 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 40
Study 28403351 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 40
Study 26496252 — intervention group
Group type: EXPERIMENTAL
Intervention: DOF plus bevacizumab
Number of subjects: 80
Study 26496252 — intervention group
Group type: COMPARATOR
Intervention: DOF
Number of subjects: 80
Study 23584670 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 12
Study 23584670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21452953 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual labeling of strollers (six different strollers labeled individually)
Number of subjects: 0
Study 21452953 — intervention group
Group type: COMPARATOR
Intervention: Category labeling of strollers (same six strollers labeled as 'stroller')
Number of subjects: 0
Study 19633103 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (subcutaneous administration, dosed to achieve Hb concentration of 13.0 g/dL, not exceeding 14.5 g/dL)
Number of subjects: 2600
Study 19633103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous administration, sham adjustments of the dose)
Number of subjects: 2600
Study 16449264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 250 microg with salmeterol 50 microg
Number of subjects: 54
Study 16449264 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone 250 microg without salmeterol
Number of subjects: 54
Study 15566435 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered communication style
Number of subjects: 250
Study 15566435 — intervention group
Group type: COMPARATOR
Intervention: Biomedical communication style
Number of subjects: 250
Study 11774820 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (TP-5) 1 mg/d for 20 days starting on 2 PBD
Number of subjects: 60
Study 11774820 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 9441152 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole for 10 days
Number of subjects: 60
Study 9441152 — intervention group
Group type: EXPERIMENTAL
Intervention: Secnidazole for 3 days
Number of subjects: 60
Study 9441152 — intervention group
Group type: EXPERIMENTAL
Intervention: Secnidazole for 7 days
Number of subjects: 60